×
About 118,952 results
U.S. FDA Approves Evofem Biosciences' Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy
https://evofem.investorroom.com/2020-05-22-U-S-FDA-Approves-Evofem-Biosciences-Phexxi-TM-lactic-acid-citric-acid-and-potassium-bitartrate-the-First-and-Only-Non-Hormonal-Prescription-Gel-for-the-Prevention-of-Pregnancy

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

Gocovri Clinical Data
https://www.gocovrihcp.com/clinical-data/
Gocovrihcp.com

May 27th, 2020 - The efficacy and safety of GOCOVRI® 274 mg were evaluated in two Phase 3, randomized, placebo-controlled trials

FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc
FDA

On May 29, 2020, the Food and Drug Administration approved ramucirumab (CYRAMZA, Eli Lilly and Company) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.

Pemazyre™ (pemigatinib) - Official Pemazyre HCP Website‎
https://hcp.pemazyre.com

Visit A Site For Healthcare Professionals To Learn Important Information On Pemazyre. Discover A Treatment Option For Your Patient And Read About The Usage And Indications. Recommended Dosing. Safety Profile. Clinical Response Rates. Prescribing Information.

Emerphed | The first and only FDA approved ready-to-use ephedrine
https://www.emerphed.com

Overdose of EMERPHED can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.

TUKYSA™ (tucatinib) tablets - Information for Physicians‎
https://www.tukysahcp.com

Request a Rep Visit, or Register to Get Updates & Stay Informed About TUKYSA™ Today. Prescribing Information. Now Approved. Learn More. Official Physician Site.

Now Approved: TRODELVY™ - Sacituzumab Govitecan-hziy‎
https://www.trodelvy.com

Official Site: Learn about TRODELVY™, Clinical Study Results. FDA approved. See Full Safety and Prescribing Information including boxed Warning. Prescribing Information. Safety. Dosing. Financial Support.

KOSELUGO™ (selumetinib) - Official Website‎
https://www.koselugo.com

Learn More Information About Now FDA-Approved KOSELUGO On The Official Site. Resources Available. Important Safety Info. Indication Info. Download Prescribing Info. Access 360 Program. Insurance coverage: Financial Support Info, Access 360 Program.

FDA approves niraparib for first-line maintenance of advanced ovarian cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA

Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer
FDA

May 5th, 2020 - On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Retevmo™ (selpercatinib)‎ - Visit The Official Site‎
https://www.retevmo.com/

View Safety & Prescribing Information On The Official Patient Site. Learn How Retevmo™ Works And How It May Help Eligible Patients. Savings & Support. Dosing and Administration. About RETEVMO™. Types: Patient Resources, Treatment Information, Safety Information.

DARZALEX Faspro™ - Info for Physicians‎
https://www.darzalexhcp.com

(daratumumab and hyaluronidase human-fihj) Learn More at the Official Physician Site. Prescription Assistance. Patient Support Program. Dosing Admin & Safety. Janssen CarePath. Official Physician Site. Learn About Multiple MOAs. Patient Dosing Schedule.

TABRECTA™ (capmatinib) - Now Approved - HCP Site‎
https://www.hcp.novartis.com/products/tabrecta/met-exon-14-skipping-mutation-nsclc/efficacy/?site=MTX-1228793GK104516&source=01030&gclid=EAIaIQobChMIqfz855_K6QIVCZezCh1p0gOqEAAYAiAAEgJWYPD_BwE&gclsrc=aw.ds

HCPs, Visit The Official Site For Information About TABRECTA™ As A Treatment Option. See If TABRECTA™ Could Be Right For Your Patients. Full Safety Profile. Patient Co-Pay Program. Mechanism Of Action. Newly FDA Approved. Official HCP Website. Clinical Trial Data.

ZEJULA® (niraparib) HCP Site - Oral Treatment Option‎
https://www.zejula.com/en/hcp

Visit our website to find information on efficacy, safety, and dosing. HCP Resources. Treatment Sequencing. Patient Stories. Prescribing Information. Dose Modification. Zejula ovarian cancer niraparib Zejula

A First-line Oral Treatment for Certain People with Gaucher Disease Type 1
http://www.cerdelga.com/healthcare-professionals.html

CERDELGA is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.

ADEMPAS (riociguat) tablets
http://adempas-us.com/hcp/

Adempas (riociguat). Visit Adempas-US.com to see full safety and prescribing information, including Boxed Warning. Learn about Adempas and the Aim Patient Support Program.

ACNIZIL™ topical gel
https://www.henryschein.com/us-en/Medical/ShopExp/Acnizil.aspx

Acnizil™ is a new first-line therapy product for mild to severe acne. It is made from a proprietary silver solution

Abbott RealTime IDH1
https://www.molecular.abbott/us/en/products/oncology/realtime-idh1

An in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs)